The UK All Party Parliamentary Group on Malaria & NTDs (APPMG) recently released a report entitled ‘Racing Against Time: Protecting the Gains Achieved in Malaria Control Against Drug Resistance’

Draft standards are expected to be ready for release for public review by August 2016.

A database of individual participant-level information could benefit schistosomiasis clinical research and treatment policies, according to a study published today in PLOS Neglected Tropical Diseases.

Malaria infection during pregnancy can seriously affect the lives of the pregnant mother, foetus and newborn baby.

WWARN’s Regional Centres were established to support researchers and public health practitioners to strengthen their skills and expertise in the field of malaria and more recently in other emerging infections.

Significant progress in malaria control and elimination has been made since 2000 - malaria mortality rates have fallen by 60 percent and over 6.2 million lives have been saved.

The Molecular Surveyor pfmdr1 & pfcrt now includes a further 34 studies, totaling more than 418 published and unpublished studies since 2001, examining data on molecular markers of antimalarial resistance from approximately 374 international locations.

The WWARN Gametocyte Carriage Study Group has published a paper in BMC Medicine confirming that the level of gametocytes in the body post-treatment is influenced by the type of artemisinin combination therapy (ACT) used.

Avoiding ‘data dumpsters’ is the key to ensuring that the drive towards open data sharing is truly useful, according to a Perspective article published in the New England Journal of Medicine today.

The latest Ebola clinical trial to be published showed that, at the dose given, the drug did not improve survival rates compared to historic controls.

First interactive online tool that displays the prevalence and degree of chloroquine resistance in P. vivax parasites from many geographic locations and time periods.

The proliferation of poor quality medicines has been described as a global pandemic that threatens the lives of millions. Poor quality medicines can have a devastating affect on the lives of patients, resulting in prolonged sickness, treatment failure, side effects, loss of income, and death.

On Monday, 25 April a group of leading researchers marked World Malaria Day and their support for the global drive to ‘End Malaria for Good’.

Two new studies, published today in the New England Journal of Medicine, announce the results from clinical trials investigating the safety and efficacy of antimalarial medicines, currently used in the wider population, on pregnant women.

The WWARN In Vitro team lead by Institut Pasteur, Cambodia, have designed a new piperaquine survival assay (PSA) that can now be used to capture the outcomes of antimalarial drug resistance to piperaquine in the laboratory.

WWARN has now joined forces with the Malaria in Pregnancy (MiP) Consortium to establish a malaria in pregnancy research programme within the WWARN data platform.

The WWARN Clinical & Molecular Scientific Groups have established a new study group to investigate the correlation between different K13 mutations and parasites that show a slow clearing clinical response in patients, the phenotype.

The ACT Consortium drug quality programme shares findings from their multi-country study that assessed the quality of over 10,000 artemisinin-based combinations, purchased in six malaria endemic countries.

New study finds evidence to show that the commonly used antimalarial drug, dihydroartemisinin-piperaquine, is failing to treat patients in some regions of Cambodia.

The World Malaria Report 2015, launched today, focuses on the great strides made against malaria across the world and looks at the challenges that lie ahead for malaria endemic countries.